 |
 |
Avigen to Present at CIBC World Markets Annual Conference Company to Review Its Breakthrough Therapies for Parkinson's Disease and Chronic Pain ALAMEDA, Calif., April 26 /PRNewswire-FirstCall/ -- Avigen, Inc. (Nasdaq: AVGN) a leader in the development of gene- based therapies for serious chronic conditions, announced that it will be presenting tomorrow, April 27, 2004, at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference, to be held in New York on April 27-28, 2004, will feature informative presentations and panels from healthcare companies, clinical investigators and research scientists. The theme of this year's conference is "Breakthrough Therapeutics: Leading Experts and Companies." Avigen will conduct an audio webcast of its presentation at CIBC, which will be held next Tuesday, April 27 from 4:45pm - 5:15pm (EDT). In keeping with the conference theme, Avigen will provide an overview of their current research and clinical plans in Parkinson 's disease and Neuropathic Pain. Avigen's presentation will focus on the company's new strategic initiative to increase its focus on DNA-based product opportunities that target serious chronic diseases with more life-threatening characteristics, creating a risk-benefit profile that favors a more accelerated subject enrollment pace and faster clinical development timelines. Specifically, Avigen is pursuing neurological disorders for diseases that have limited treatment options and significantly impaired life expectancy and quality of life. Avigen will discuss its two CNS product candidates. The first is AV201 for the treatment of Parkinson's disease. After extensive preclinical research, Avigen filed an Investigational New Drug (IND) application seeking clearance to begin clinical testing of AV201. The second program is AV333 for the treatment of severe chronic pain. AV333 represents a new approach to the treatment of severe chronic pain, with demonstrated success in reversing neuropathic pain in established animal models. Avigen has obtained an exclusive license to new technology for the treatment of severe chronic pain. To listen to the live webcast follow this URL link: http://www.veracast.com/webcasts/cibcwm/biotech04/98116251.cfm About Avigen: Avigen, Inc., based in the San Francisco Bay Area, focuses on the development of DNA-based drugs for serious chronic conditions. Avigen's proposed gene delivery products are designed for direct administration to patients in order to achieve expression of therapeutic proteins within the body. Patients or physicians who would like more information should contact the Clinical Development Department at [log in to unmask] or call at 877-4-AVIGEN (428-4436). Additional information on Avigen's proprietary gene delivery products can be found at http://www.avigen.com SOURCE Avigen, Inc. Web Site: http://www.avigen.com SOURCE: PR Newswire (press release) http://tinyurl.com/ywsrd * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn